查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587790

临床试验中心网路市场规模、份额和趋势分析报告：2025-2030 年按治疗领域、阶段、最终用途、地区和细分市场进行的预测

Clinical Trial Investigative Site Network Market Size, Share & Trends Analysis Report By Therapeutic Areas (Oncology, Cardiology), By Phase (Phase I, Phase II), By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

临床试验站点网路市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，预计到 2030 年，全球临床试验站点网路市场规模将达到 137.6 亿美元，2025 年至 2030 年复合年增长率为 7.85%。

药物研发投资的增加、对新治疗方法的需求增加以及与临床试验设施管理相关的併发症是推动该行业成长的一些主要因素。过去五年来，临床试验持续增加。例如，根据ClinicalTrials.gov的数据，2018年註册的临床试验超过262,298项，截至2022年9月，註册的临床试验超过399,518项。随着研究经费的增加，临床试验预计将进一步成长。

预计这将推动大流行后的行业成长。人们越来越关注降低与临床研究相关的成本。僱用临床试验中心网路来支持监管职能，提高参与者的註册率，并协助资料管理和品质保证。它还提高了流程合规性并减少了每个临床试验中的流程问题，有助于更快地启动临床试验并缩短临床试验持续时间。这些因素支持了对临床实验站点网路的需求。各国政府正积极尝试透过提供扣除额来改善研究和发展。例如，2022年1月，印度政府宣布将为研发提供高达200%的加权平均税额扣抵抵免。

这些措施预计将改善药物研发活动并促进产业成长。根据 IQVIA 的肿瘤学趋势报告，癌症临床试验在过去十年中持续增加。例如，2011年註册了1,242项临床试验，截至2021年，已註册2,335项临床试验。由于癌症盛行率不断增加，癌症临床试验的数量预计将进一步增加。预计这将增加疫情后癌症临床试验中对临床实验站点网路的需求。

临床试验现场网路市场报告亮点

  • 以治疗领域来看，癌症领域在2024年以35.1%的份额占据市场主导地位。针对癌症的临床试验数量的增加是支持该领域成长的关键因素之一。
  • 第三阶段的患者数量比其他阶段更多，支持了临床实验现场网路的需求。
  • 按最终用途划分，CRO（合约委外研发机构）产业预计在预测期内复合年增长率最快。
  • 这是由于临床实验网络和 CRO 之间的临床试验合作伙伴关係数量不断增加。
  • 亚太地区的临床试验外包正在增加，预计在预测期内复合年增长率最快。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章临床试验现场网路市场的变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章临床试验设施网路市场：阶段估计与趋势分析

  • 细分仪表板
  • 全球临床试验站点网路市场：相变分析
  • 2018年至2030年分阶段临床试验中心网路规模及趋势分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章临床试验设施网路市场：治疗领域的估计与趋势分析

  • 细分仪表板
  • 全球临床试验中心网路市场：治疗领域波动分析
  • 2018年至2030年全球临床试验中心网路规模及趋势分析：依治疗领域
  • 肿瘤学
  • 心臟病学
  • 中枢神经系统症状
  • 疼痛管理
  • 内分泌
  • 其他的

第六章临床试验设施网路市场：最终用途估计与趋势分析

  • 细分仪表板
  • 全球临床试验站点网路市场；
  • 2018-2030 年全球临床试验中心网路规模与趋势分析（依最终用途）
  • 製药和生物製药公司
  • 医疗设备公司
  • 其他的

第七章临床试验设施网路市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 2024 年企业市场分析
  • 公司简介
    • ICON Plc
    • Velocity Clinical Research
    • IQVIA Inc.
    • Elligo Health Research
    • WCG Clinical
    • ClinChoice
    • Access Clinical Trials Inc.
    • FOMAT Medical Research, Inc.
    • SGS Societe Generale de Surveillance SA.
    • KV Clinical Research
    • SMO-Pharmina
    • Xylem Research LLP
    • The Aurum Institute
Product Code: GVR-4-68039-986-6

Clinical Trial Investigative Site Network Market Growth & Trends:

The global clinical trial investigative site network market size is estimated to reach USD 13.76 billion by 2030, expanding at a CAGR of 7.85% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing investments in pharmaceutical R&D, increasing demand for new therapies and complications associated with site management of clinical trials are some of the major factors driving the growth of the industry. There has been a consistent rise the clinical trials in the last 5 years. For instance, according to ClinicalTrials.gov, over 262,298 trials were registered in 2018, whereas as of September 2022, over 399,518 trials were registered. The clinical trials are expected to grow even further as the funding for research improves.

This is expected to propel the growth of the industry post-pandemic. There is a growing focus on reducing the cost associated with clinical research. Hiring a clinical trial investigative site network supports the regulatory function, improves the enrollment of participants, assists in data management, and quality assurance. It increases process compliance, reduces process issues with each trial, and helps with faster trial initiations, and shorter trial timelines. These factors are supporting the demand for clinical investigative site networks. The governments are actively trying to improve R&D by providing tax deductions. For instance, in January 2022, the Indian government stated that it is providing a weighted average tax deduction of up to 200% in R&D.

Such initiatives are expected to improve the R&D activities on drugs and thus support industry growth. According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials for cancer is expected to rise even further owing to the growing prevalence of the disease. This is expected to improve the demand for clinical investigative site networks for cancer clinical trials post-pandemic.

Clinical Trial Investigative Site Network Market Report Highlights:

  • Based on therapeutic areas, the oncology segment dominated the market with a share of 35.1% in 2024. The growing number of clinical trials for cancer is one of the major factors supporting the segment growth
  • The phase III segment led the industry in 2024 with the maximum revenue share as this phase includes a greater number of patients than other phases, thus supporting the demand for clinical investigative site network
  • Based on end-use, the Contract Research Organizations (CROs) segment is anticipated to witness the fastest CAGR over the forecast perio
  • This is owing to the increasing number of partnerships among site networks and CROs for clinical studies
  • Asia Pacific is anticipated to register the fastest CAGR over the forecast period due to a rise in the outsourcing of clinical trials in this region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Clinical Trial Investigative Site Network Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Increasing Technological Advancements
      • 3.2.1.3. Increasing Partnerships and Collaborations
      • 3.2.1.4. Expansion of Decentralized Trials
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rising Costs of Clinical Trials
      • 3.2.2.2. Limited Awareness and Training
      • 3.2.2.3. Data Privacy Concerns
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Trial Investigative Site Network Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Clinical Trial Investigative Site Network Market; Phase Movement Analysis
  • 4.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Clinical Trial Investigative Site Network Market: Therapeutic Areas Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Clinical Trial Investigative Site Network Market; Therapeutic Areas Movement Analysis
  • 5.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiology
    • 5.5.1. Cardiology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. CNS Conditions
    • 5.6.1. CNS Conditions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Pain management
    • 5.7.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Endocrine
    • 5.8.1. Endocrine market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Clinical Trial Investigative Site Network Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Clinical Trial Investigative Site Network Market; End Use Movement Analysis
  • 6.3. Global Clinical Trial Investigative Site Network Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & biopharmaceutical companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Medical Device Companies
    • 6.5.1. Medical device companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Clinical Trial Investigative Site Network Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. ICON Plc
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Velocity Clinical Research
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. IQVIA Inc.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Elligo Health Research
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. WCG Clinical
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. ClinChoice
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Access Clinical Trials Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. FOMAT Medical Research, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. SGS Societe Generale de Surveillance SA.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. KV Clinical Research
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. SMO-Pharmina
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Service benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Xylem Research LLP
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Service benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. The Aurum Institute
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Service benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 5 Global Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Clinical Trial Investigative Site Network, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Clinical Trial Investigative Site Network, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 9 Global Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 10 North America Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 13 U.S. Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Canada Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 16 Canada Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 19 Mexico Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 20 UK Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 21 UK Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 22 UK Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Germany Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 25 Germany Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 26 France Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 27 France Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 28 France Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Italy Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Italy Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 31 Italy Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Spain Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Spain Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 34 Spain Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Sweden Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 37 Sweden Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Norway Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Norway Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 40 Norway Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Denmark Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Denmark Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 43 Denmark Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 44 India Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 45 India Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 46 India Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 47 China Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 48 China Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 49 China Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Japan Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 51 Japan Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 52 Japan Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 53 India Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 54 India Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 55 India Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Australia Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Australia Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 58 Australia Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 59 Thailand Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 60 Thailand Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 61 Thailand Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 63 South Korea Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 64 South Korea Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Brazil Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 67 Brazil Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 68 Argentina Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Argentina Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 70 Argentina Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 71 Saudi Arabia Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Saudi Arabia Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 73 Saudi Arabia Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 74 UAE Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 75 UAE Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 76 UAE Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Kuwait Clinical Trial Investigative Site Network, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Kuwait Clinical Trial Investigative Site Network, by Therapeutic Areas, 2018 - 2030 (USD Million)
  • Table 79 Kuwait Clinical Trial Investigative Site Network, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1. Information Procurement
  • Fig. 2. Primary Research Pattern
  • Fig. 3. Market Research Approaches
  • Fig. 4. Value Chain-Based Sizing & Forecasting
  • Fig. 5. Market Formulation & Validation
  • Fig. 6. Clinical Trial Investigative Site Network, Market Segmentation
  • Fig. 7. Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8. Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9. Porter's Five Forces Analysis
  • Fig. 10. PESTEL Analysis
  • Fig. 11. Regional Marketplace: Key Takeaways
  • Fig. 12. Global Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13. Global Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14. Global Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15. Global Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16. Global Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 17. Global Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 18. Global Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 19. Global Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 20. Global Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 21. Global Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 22. Global Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 23. Global Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 24. Global Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 25. North America Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 26. North America Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 27. North America Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 28. North America Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 29. North America Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 30. North America Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 31. North America Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 32. North America Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 33. North America Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 34. North America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 35. North America Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 36. North America Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 37. North America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 38. U.S. Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 39. U.S. Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 40. U.S. Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 41. U.S. Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 42. U.S. Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 43. U.S. Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 44. U.S. Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 45. U.S. Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 46. U.S. Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 47. U.S. Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 48. U.S. Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 49. U.S. Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 50. U.S. Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 51. Canada Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 52. Canada Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 53. Canada Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 54. Canada Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 55. Canada Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 56. Canada Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 57. Canada Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 58. Canada Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 59. Canada Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 60. Canada Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 61. Canada Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 62. Canada Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 63. Canada Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 64. Mexico Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 65. Mexico Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 66. Mexico Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 67. Mexico Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 68. Mexico Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 69. Mexico Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 70. Mexico Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 71. Mexico Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 72. Mexico Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 73. Mexico Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 74. Mexico Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 75. Mexico Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 76. Mexico Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 77. Europe Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 78. Europe Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 79. Europe Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 80. Europe Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 81. Europe Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 82. Europe Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 83. Europe Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 84. Europe Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 85. Europe Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 86. Europe Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 87. Europe Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 88. Europe Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 89. Europe Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 90. UK Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 91. UK Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 92. UK Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 93. UK Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 94. UK Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 95. UK Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 96. UK Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 97. UK Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 98. UK Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 99. UK Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 100. UK Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 101. UK Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 102. UK Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 103. Germany Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 104. Germany Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 105. Germany Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 106. Germany Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 107. Germany Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 108. Germany Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 109. Germany Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 110. Germany Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 111. Germany Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 112. Germany Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 113. Germany Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 114. Germany Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 115. Germany Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 116. France Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 117. France Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 118. France Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 119. France Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 120. France Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 121. France Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 122. France Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 123. France Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 124. France Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 125. France Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 126. France Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 127. France Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 128. France Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 129. Spain Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 130. Spain Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 131. Spain Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 132. Spain Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 133. Spain Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 134. Spain Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 135. Spain Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 136. Spain Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 137. Spain Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 138. Spain Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 139. Spain Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 140. Spain Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 141. Spain Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 142. Italy Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 143. Italy Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 144. Italy Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 145. Italy Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 146. Italy Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 147. Italy Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 148. Italy Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 149. Italy Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 150. Italy Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 151. Italy Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 152. Italy Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 153. Italy Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 154. Italy Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 155. Denmark Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 156. Denmark Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 157. Denmark Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 158. Denmark Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 159. Denmark Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 160. Denmark Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 161. Denmark Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 162. Denmark Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 163. Denmark Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 164. Denmark Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 165. Denmark Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 166. Denmark Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 167. Denmark Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 168. Sweden Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 169. Sweden Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 170. Sweden Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 171. Sweden Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 172. Sweden Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 173. Sweden Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 174. Sweden Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 175. Sweden Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 176. Sweden Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 177. Sweden Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 178. Sweden Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 179. Sweden Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 180. Sweden Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 181. Norway Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 182. Norway Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 183. Norway Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 184. Norway Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 185. Norway Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 186. Norway Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 187. Norway Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 188. Norway Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 189. Norway Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 190. Norway Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 191. Norway Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 192. Norway Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 193. Norway Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 194. Asia Pacific Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 195. Asia Pacific Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 196. Asia Pacific Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 197. Asia Pacific Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 198. Asia Pacific Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 199. Asia Pacific Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 200. Asia Pacific Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 201. Asia Pacific Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 202. Asia Pacific Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 203. Asia Pacific Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 204. Asia Pacific Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 205. Asia Pacific Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 206. Asia Pacific Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 207. Japan Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208. Japan Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209. Japan Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210. Japan Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211. Japan Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 212. Japan Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 213. Japan Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 214. Japan Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 215. Japan Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 216. Japan Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 217. Japan Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 218. Japan Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 219. Japan Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 220. China Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 221. China Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 222. China Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 223. China Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 224. China Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 225. China Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 226. China Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 227. China Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 228. China Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 229. China Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 230. China Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 231. China Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 232. China Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 233. India Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 234. India Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 235. India Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 236. India Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 237. India Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 238. India Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 239. India Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 240. India Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 241. India Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 242. India Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 243. India Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 244. India Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 245. India Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 246. Australia Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 247. Australia Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 248. Australia Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 249. Australia Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 250. Australia Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 251. Australia Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 252. Australia Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 253. Australia Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 254. Australia Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 255. Australia Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 256. Australia Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 257. Australia Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 258. Australia Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 259. Thailand Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 260. Thailand Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 261. Thailand Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 262. Thailand Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 263. Thailand Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 264. Thailand Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 265. Thailand Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 266. Thailand Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 267. Thailand Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 268. Thailand Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 269. Thailand Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 270. Thailand Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 271. Thailand Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 272. South Korea Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 273. South Korea Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 274. South Korea Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 275. South Korea Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 276. South Korea Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 277. South Korea Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 278. South Korea Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 279. South Korea Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 280. South Korea Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 281. South Korea Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 282. South Korea Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 283. South Korea Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 284. South Korea Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 285. Latin America Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 286. Latin America Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 287. Latin America Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 288. Latin America Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 289. Latin America Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 290. Latin America Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 291. Latin America Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 292. Latin America Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 293. Latin America Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 294. Latin America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 295. Latin America Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 296. Latin America Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 297. Latin America Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 298. Brazil Clinical Trial Investigative Site Network, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 299. Brazil Clinical Trial Investigative Site Network, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 300. Brazil Clinical Trial Investigative Site Network, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 301. Brazil Clinical Trial Investigative Site Network, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 302. Brazil Clinical Trial Investigative Site Network, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 303. Brazil Clinical Trial Investigative Site Network, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 304. Brazil Clinical Trial Investigative Site Network, For CNS Conditions, 2018 - 2030 (USD Million)
  • Fig. 305. Brazil Clinical Trial Investigative Site Network, For Pain Management, 2018 - 2030 (USD Million)
  • Fig. 306. Brazil Clinical Trial Investigative Site Network, For Endocrine, 2018 - 2030 (USD Million)
  • Fig. 307. Brazil Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)
  • Fig. 308. Brazil Clinical Trial Investigative Site Network, For Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 309. Brazil Clinical Trial Investigative Site Network, For Medical Device Companies, 2018 - 2030 (USD Million)
  • Fig. 310. Brazil Clinical Trial Investigative Site Network, For Others, 2018 - 2030 (USD Million)